Clinical Research Directory
Browse clinical research sites, groups, and studies.
GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results
Sponsor: Suzhou Genhouse Bio Co., Ltd.
Summary
Evaluate the safety and tolerability of GH35 in patients with KRAS mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in patients with KRAS mutant advanced solid tumors.
Official title: A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of GH35 Tablets in Patients Harboring With G12C Mutation in Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2021-09-27
Completion Date
2025-12-12
Last Updated
2024-07-08
Healthy Volunteers
No
Interventions
GH35 Tablet
GH35 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.
Locations (2)
Fudan University Zhongshan Hospital
Shanghai, Shanghai Municipality, China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China